Case Reports in Oncology最新文献

{"title":"Primary Salivary Clear Cell Carcinoma with Response to Checkpoint Inhibition: Case Report and Review of the Literature.","authors":"Samuel F Schaeffer, Matthew M Mirsky","doi":"10.1159/000552473","DOIUrl":"10.1159/000552473","url":null,"abstract":"<p><strong>Introduction: </strong>Primary salivary clear cell carcinoma (CCC) is a rare tumor of the minor salivary glands that is often seen as low-grade and responsive to resection. Limited data exist for its response to systemic chemotherapy or immune therapy.</p><p><strong>Case presentation: </strong>A 76-year-old male presented with recurrent, widely metastatic salivary CCC over 3 years after local resection with bilateral selective neck dissections. Advanced imaging showed biopsy-confirmed metastasis to the omentum, lungs, pleural effusion, and lymph nodes. Stable disease was achieved with carboplatin/paclitaxel therapy, but treatment was not tolerated by the patient due to side effects. Patient has been treated with single-agent pembrolizumab for 12 cycles with continued disease control and improvement in effusion.</p><p><strong>Conclusion: </strong>Despite the low immunogenicity of this tumor, a clinically positive response was achieved with PD-(L)1 inhibition. More research is needed to identify systemic targeted therapies for CCC and tumors with low immunogenicity.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1760-1766"},"PeriodicalIF":0.7,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case Report of Bilateral Thyroid Thymic Carcinoma with Multiple Cervical Lymph Node Metastases: Clinical Manifestations and Imaging Characteristics.","authors":"Xiaojuan Zheng, Zhuomin Chen","doi":"10.1159/000551983","DOIUrl":"10.1159/000551983","url":null,"abstract":"<p><strong>Introduction: </strong>Intrathyroidal thymic carcinoma (ITTC) is a rare low-grade malignant tumor arising within the thyroid gland. It exhibits histological and immunophenotypic features similar to thymic carcinoma. Due to its rarity and non-specific imaging findings, preoperative diagnosis remains challenging.</p><p><strong>Case presentation: </strong>We report a case of a 60-year-old male who presented with hoarseness and dysphagia. Ultrasound revealed multiple bilateral thyroid nodules with irregular margins and heterogeneous internal echoes, along with bilateral cervical lymphadenopathy. Enhanced CT showed heterogeneous enhancement of the thyroid and enlarged lymph nodes. The patient underwent extended radical resection of bilateral thyroid cancer with mediastinal lymph node dissection. Postoperative pathology and immunohistochemistry confirmed the diagnosis of bilateral thyroid thymic carcinoma with multiple cervical lymph node metastases.</p><p><strong>Conclusion: </strong>ITTC should be considered in the differential diagnosis of thyroid nodules with suspicious ultrasound features, especially when associated with cervical lymph node metastases. Positive expression of CD5 and CD117 with negative expression of Tg and TTF-1 is diagnostic. Treatment follows principles similar to those for thymic carcinoma, and complete surgical resection remains the mainstay.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1594-1600"},"PeriodicalIF":0.7,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Continuation Therapy with Nab-Paclitaxel and Bevacizumab ± Anti-PD-1 in Advanced Non-Small Cell Lung Cancer: Case Reports and Mechanistic Insights.","authors":"Xiaofen Pan, Xueying Li, Jiehao Liao, Suhua Chen, Bo Wang","doi":"10.1159/000551998","DOIUrl":"10.1159/000551998","url":null,"abstract":"<p><strong>Introduction: </strong>The role of nab-paclitaxel in non-small cell lung cancer (NSCLC) as long-term continuation therapy remains underexplored, particularly in combination with anti-angiogenic agents and immunotherapy. We present 2 cases of advanced NSCLC achieving prolonged progression-free survival with nab-paclitaxel-based regimens.</p><p><strong>Case presentation: </strong>Case 1 (ALK-positive) received nab-paclitaxel + bevacizumab every 4 weeks for more than 48 months. Case 2 (driver-negative) received nab-paclitaxel + bevacizumab + toripalimab every 6-8 weeks for 24 months. Both patients maintained partial regression of disease, minimal toxicity (no grade, ≥3 adverse events), and preserved quality of life.</p><p><strong>Conclusion: </strong>The literature review highlights synergistic mechanisms of chemotherapy, anti-angiogenesis, and immunotherapy, supported by trials such as IMpower150 and KEYNOTE-407. Low-dose, extended-interval nab-paclitaxel combined with anti-angiogenesis and immunotherapy may offer a feasible maintenance strategy, warranting validation in prospective trials.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1732-1739"},"PeriodicalIF":0.7,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Right-To-Left Stage Migration in Advanced Hepatocellular Carcinoma: A Case Report of a Successful Multimodal Approach.","authors":"Anna Nappi, Rocco Morra, Sergio Facchini, Nicoletta Zanaletti, Marco Borrelli, Francesco Fiore, Luca Tarotto, Salvatore Stilo, Francesco Izzo, Mauro Piccirillo, Antonio Avallone","doi":"10.1159/000552976","DOIUrl":"10.1159/000552976","url":null,"abstract":"<p><strong>Introduction: </strong>Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. Over the last decade, the therapeutic landscape of advanced HCC has substantially evolved following the introduction of immune checkpoint inhibitor-based combinations, including anti-programmed death ligand 1 (PD-L1) plus anti-vascular endothelial growth factor agents and dual immune checkpoint blockade strategies targeting programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Nevertheless, the optimal timing and integration of locoregional therapies following systemic treatment remain poorly defined, particularly in patients achieving major radiological responses. In this setting, multidisciplinary evaluation is essential to guide individualized therapeutic strategies.</p><p><strong>Case presentation: </strong>Herein we present the case of a 68-year-old male with advanced HCC. First-line systemic treatment with atezolizumab plus bevacizumab was administered for 6 cycles, resulting in a major radiological and biochemical response. Following multidisciplinary discussion, selective transarterial embolization was performed as consolidative locoregional treatment. At the last follow-up evaluation at 42 months, the patient remained alive with no evidence of disease recurrence.</p><p><strong>Conclusion: </strong>Our case highlights the potential role of a multidisciplinary therapeutic strategy in selected patients with advanced HCC. The integration of systemic immunotherapy-based treatment with consolidative locoregional therapy may enable successful downstaging and durable disease control, suggesting a possible role of leftward treatment stage migration in advanced unresectable HCC.</p><p><strong>Core tip: </strong>The optimal integration of systemic immunotherapy and locoregional treatment in advanced HCC represents a novel field. No clear evidence has yet been provided regarding the role of systemic therapy as induction in BCLC stage C. Our case report suggests that atezolizumab plus bevacizumab and multidisciplinary approach could improve survival outcomes and treatment definition in selected, advanced HCC patients: it also highlights the importance of interdisciplinary interactions and collaboration in order to ensure the correct therapeutic sequencing.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1601-1609"},"PeriodicalIF":0.7,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149080022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Traditional Chinese and Western Medicine for Severe Tislelizumab-Induced Rash: A Case Report.","authors":"Boya Wang, Yan Zhang, Jianglin Wu, Sicheng Yi, Ying Yan, Yuhan Deng, Kui Zhang","doi":"10.1159/000553623","DOIUrl":"10.1159/000553623","url":null,"abstract":"<p><strong>Introduction: </strong>Programmed death receptor 1 inhibitors are widely used tumor immunotherapy agents, yet they frequently trigger immune-related adverse events (irAEs), among which severe cutaneous toxicities are life-threatening and often interrupt anti-tumor treatment. Conventional Western medicine relying on glucocorticoids carries notable side effects, while integrated traditional Chinese medicine and Western medicine (TCM-WM) offers a promising alternative therapeutic strategy. This work aims to explore the clinical efficacy and safety of combined TCM-WM intervention for severe tislelizumab-induced cutaneous irAEs, elaborate traditional Chinese medicine (TCM) syndrome differentiation logic, and accumulate clinical evidence for managing such severe skin adverse reactions.</p><p><strong>Case presentation: </strong>A 71-year-old male patient with right lung squamous cell carcinoma complicated by supraclavicular lymph node metastasis developed grade 3 severe cutaneous irAE after tislelizumab immunotherapy, diagnosed with TCM syndrome of intermingled damp-heat, stasis, and toxin. Comprehensive Western medicine treatment (glucocorticoids, antihistamines, topical anti-inflammatory ointments, and analgesics) combined with individualized oral modified TCM granules, external herbal washing, and characteristic TCM therapies was implemented. After 12 days of inpatient treatment and 3 months of continuous follow-up, the patient's severe rash, skin pain, and pruritus were fully resolved without recurrence. The duration of intravenous glucocorticoid administration was shortened to only 7 days followed by oral tapering, and no significant adverse reactions occurred during the whole treatment course.</p><p><strong>Conclusion: </strong>Integrated TCM-WM demonstrates synergistic efficacy in the treatment of severe tislelizumab-induced cutaneous irAEs by regulating immune balance and eliminating pathogenic factors. It provides a valuable therapeutic option for such patients and warrants further validation in larger sample studies.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1330-1342"},"PeriodicalIF":0.7,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13589653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149007976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pseudoprogression after Axi-cel in Primary Refractory PMBCL following Failed Bridging: Case Report and Management Considerations.","authors":"Philip Alan Speicher, Marie-Noelle Kronig, Urban Novak","doi":"10.1159/000553567","DOIUrl":"10.1159/000553567","url":null,"abstract":"<p><strong>Introduction: </strong>Primary mediastinal large B-cell lymphoma (PMBCL) is a rare, aggressive lymphoma with limited therapeutic options in the relapsed or refractory setting. Axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, has shown promising efficacy; yet treatment decisions remain challenging in patients with rapidly progressive disease and high tumor burden.</p><p><strong>Case presentation: </strong>We report a 29-year-old woman with primary chemotherapy-refractory PMBCL who developed fulminant extranodal disease progression despite radiotherapy and systemic bridging therapy prior to planned axi-cel infusion. Following CAR T-cell therapy, she experienced grade 2 cytokine release syndrome and grade 3 immune effector cell-associated neurotoxicity syndrome, alongside clinical deterioration and radiological findings suggestive of disease progression. Notably, pronounced CAR T-cell expansion preceded biochemical improvement and subsequent radiological tumor regression, consistent with pseudoprogression rather than true treatment failure.</p><p><strong>Conclusion: </strong>Despite initially misleading clinical and imaging findings in the context of suboptimal baseline conditions, the patient achieved a durable complete remission and remains disease-free 23 months post-CAR T-cell therapy, with excellent quality of life. This case highlights the critical importance of recognizing immune-mediated flare phenomena to guide clinical decision-making and avoid premature treatment discontinuation or misclassification of therapeutic failure.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1754-1759"},"PeriodicalIF":0.7,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carboplatin, Etoposide, and Durvalumab for Extensive-Stage Small Cell Lung Cancer in a Patient Undergoing Maintenance Hemodialysis: A Case Report.","authors":"Morimi Fujita, Ninso Matsunaga, Hiroyuki Tsuji, Yosuke Tamura, Kenjiro Tsuruoka, Takahiko Nakamura, Soichiro Ikeda, Yasuhito Fujisaka","doi":"10.1159/000552719","DOIUrl":"10.1159/000552719","url":null,"abstract":"<p><strong>Introduction: </strong>Patients undergoing maintenance hemodialysis exhibit a unique immunological state characterized by chronic inflammation and T-cell dysfunction. Evidence regarding the efficacy and safety of combination chemoimmunotherapy in dialysis patients remains extremely limited.</p><p><strong>Case report: </strong>We report a case of extensive-stage small cell lung cancer (performance status 1, cT1cN2M1c, stage IVB) in a patient undergoing maintenance hemodialysis who received 4 cycles of carboplatin (300 mg/m², day 1), etoposide (50 mg/m², days 1 and 3), and durvalumab (1,500 mg/body, day 1). Treatment was safely continued after adjusting the dosing schedule and dose levels in accordance with the dialysis schedule. Although new brain metastases developed during treatment and whole-brain radiotherapy was administered, computed tomography after 4 cycles demonstrated a partial response, and durvalumab maintenance therapy was subsequently continued. Grade 4 thrombocytopenia and grade 3 anemia and neutropenia were observed as adverse events; however, these were manageable with transfusion support and dose reduction. Disease progression was subsequently observed.</p><p><strong>Conclusion: </strong>Carboplatin, etoposide, and durvalumab can provide meaningful therapeutic benefit even in patients undergoing maintenance hemodialysis when adverse events are appropriately managed.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1740-1746"},"PeriodicalIF":0.7,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synchronous Chronic Myeloid Leukemia and Metastatic Papillary Thyroid Carcinoma: A Case Report of a Diagnostic and Therapeutic Challenge.","authors":"Nada SalahAldin Ishti, Nagham N Alkhateeb, Khaled Alhashlamon, Shoroq Hamadneh, Aysha Halayqa, Nidal E M Al Jebrini, Izzeddin Ghazi Eqtait","doi":"10.1159/000553529","DOIUrl":"10.1159/000553529","url":null,"abstract":"<p><strong>Introduction: </strong>The synchronous presentation of chronic myeloid leukemia (CML) and papillary thyroid carcinoma (PTC) is rare and may create important diagnostic and therapeutic challenges.</p><p><strong>Case presentation: </strong>A 36-year-old woman presented with leukocytosis and was diagnosed with chronic-phase CML. During the initial workup, ^18F-FDG PET/CT showed diffuse marrow activity together with mild-to-moderate uptake in selected cervical and right paratracheal lymph nodes. Neck imaging demonstrated a nodular thyroid gland and cervical lymphadenopathy with suspicious features including cystic change and calcifications, raising concern for a synchronous second primary malignancy. Fine-needle aspiration confirmed PTC, and nodal sampling established metastatic PTC. Hematologic stabilization with nilotinib was initiated before surgery. The patient subsequently underwent total thyroidectomy with bilateral neck dissection. Histopathology revealed multifocal PTC with lymphatic invasion, extensive nodal metastases (59/67 lymph nodes positive), and extranodal extension. Final staging was pT2N1bM0, corresponding to AJCC 8th edition stage I.</p><p><strong>Conclusion: </strong>This case highlights the importance of careful evaluation of atypical imaging findings in patients with newly diagnosed CML and the critical role of tissue confirmation in distinguishing leukemic disease from a synchronous second primary malignancy. It also illustrates the complexity of treatment sequencing and the importance of multidisciplinary management in patients with dual primary cancers.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1747-1753"},"PeriodicalIF":0.7,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Statement: Paper by Rudrakshi Mahaldar, Saurabh Raj, Anindya Halder, Vijay Kannaujiya, Dhiraj Mallik, Banyeswar Pal, Bishal Saha, Subhra Banerjee, Shafayat Anjum, Subinay Mandal, Vinesh B and Shreya Chopra entitled \"Rare Presentation of Spontaneous Transomental Hernia in an Elderly Oncology Patient: Diagnostic Vigilance and Surgical Management\" [Case Rep Oncol. 2025;18:1307-1313; https://doi.org/10.1159/000548259].","authors":"","doi":"10.1159/000553062","DOIUrl":"10.1159/000553062","url":null,"abstract":"","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1066"},"PeriodicalIF":0.7,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13427323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148652827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gemcitabine, Cisplatin, and Durvalumab for Alpha-Fetoprotein-Producing Cancer of Unknown Primary Suspected from the Biliary Tract: A Case Report.","authors":"Kei Saito, Shuzo Nomura, Mariko Fujisawa, Mai Kitahara, Yoko Oki, Noriyuki Kuniyoshi, Ryota Masuzaki, Naoki Matsumoto, Shinobu Masuda, Hirofumi Kogure","doi":"10.1159/000553541","DOIUrl":"10.1159/000553541","url":null,"abstract":"<p><strong>Introduction: </strong>Cancer of unknown primary (CUP) often presents with distant metastases, and chemotherapy remains the standard treatment. Chemotherapeutic regimens are selected based on tumor marker profiles and immunohistochemical staining of tumor cells, with the most suitable agents chosen according to the presumed primary site. Until recently, chemotherapy for biliary tract cancer has typically consisted of a combination of gemcitabine and cisplatin (CDDP). However, immune checkpoint inhibitors (ICIs) have also been introduced in recent years.</p><p><strong>Case presentation: </strong>We report the case of a 67-year-old man who was found to have elevated serum alpha-fetoprotein (AFP) levels and enlarged lymph nodes at the hepatic on abdominal-pelvic CT. EUS-FNA/B and laparotomy biopsy of the lymph nodes confirmed a diagnosis of AFP-producing adenocarcinoma. Immunohistochemical staining demonstrated positivity for CA19-9, CK19, and CK20, suggesting a biliary tract origin. After initial chemotherapy treatment, the regimen was switched to a combination of gemcitabine, combination of gemcitabine and cisplatin, and durvalumab (GCD), and treatment was continued. Six months after initiating GCD therapy, the patient achieved a partial response on CT imaging and was transitioned to durvalumab monotherapy for maintenance. Tumor shrinkage persisted, and maintenance therapy with durvalumab alone was successfully sustained for 24 months. Following subsequent disease progression, rechallenge with GCD therapy again proved effective, and a 3-year overall survival was achieved.</p><p><strong>Conclusion: </strong>Although CUP generally carries a poor prognosis, GCD therapy may represent an effective option for CUP with suspected biliary tract origin.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1323-1329"},"PeriodicalIF":0.7,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}